サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1298398

マイコプラズマ検査市場：製品別、技術別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

Mycoplasma Testing Market By Product, By Technology, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日: | 発行: Allied Market Research | ページ情報: 英文 400 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
マイコプラズマ検査市場：製品別、技術別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年
出版日: 2023年04月01日
発行: Allied Market Research
ページ情報: 英文 400 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

マイコプラズマ検査市場は、2022年には7億米ドルと評価され、2023年から2032年にかけて11.7%のCAGRを示し、2032年には22億4,310万米ドルに達すると推定されます。

Mycoplasma Testing Market-IMG1

マイコプラズマ検査は、細胞培養サンプル中のマイコプラズマ汚染の有無を検出するために使用されます。マイコプラズマは細胞壁を持たない細菌の一種で、検出や細胞培養からの除去が困難です。マイコプラズマの混入は、細胞培養において、増殖特性の変化、遺伝子発現の変化、実験結果の悪化など、様々な問題を引き起こす可能性があります。したがって、実験結果の正確さと信頼性を保証するために、細胞培養物のマイコプラズマ汚染を定期的に検査することが不可欠です。マイコプラズマ検査は、ワクチン、ウイルス培養、その他のバイオ医薬品の検査プロセスにおいて重要です。

マイコプラズマ検査市場の成長は、生物製剤とバイオシミラーの需要の増加、細胞培養の汚染事例の急増、医薬品開発のための新技術の採用の増加によってもたらされます。生物製剤とバイオシミラーは生きた細胞を用いて製造される複雑な医薬品であり、製造過程でマイコプラズマに汚染される可能性があります。そのため、食品医薬品局（FDA）や欧州医薬品庁（EMA）などの規制機関は、生物製剤やバイオシミラーが使用承認される前に、マイコプラズマ汚染の有無を検査することを求めています。このため、マイコプラズマ検査サービスの需要が急増しています。例えば、2021年の欧州におけるバイオシミラー競合の影響に関するIQVIAのレポートによると、2020年には約9つのバイオシミラーが承認され、2021年には7つのバイオシミラーが承認されました。このように、生物製剤とバイオシミラーの承認と需要の増加は、マイコプラズマ検査の需要の増加をもたらしています。

さらに、バイオ医薬品業界における細胞培養汚染の発生件数の増加や臨床試験の世界化が市場成長を後押しする主な要因となっています。臨床試験は複数の国や地域で実施されるため、試験参加者の安全性と試験データの正確性を確保できるマイコプラズマ検査サービスが必要とされています。このため、標準化された検査要件を満たすマイコプラズマ検査サービスや製品に対する需要が高まっています。

しかし、マイコプラズマ検査製品のコストが高いため、バイオ医薬品企業での採用が制限され、それが市場の成長を抑制しています。例えば、細胞培養におけるマイコプラズマ汚染の検出に使用されるSouthernBiotech社のMycoplasma Detection Kitの価格は約200-230ドルです。さらに、培養ベースのマイコプラズマ検査サービスの価格は、サンプルあたり約250-300ドルです。このように、マイコプラズマ検査製品やサービスのコストが高いことは、市場の成長にマイナスの影響を与えます。

一方、米国、ドイツ、中国などの先進国や新興国におけるマイコプラズマ検査需要の増加は、予測期間中、マイコプラズマ検査市場に大きなビジネスチャンスをもたらすと期待されています。

マイコプラズマ検査市場は、製品、技術、用途、エンドユーザー、地域によって区分されます。製品ベースでは、市場は機器、キット＆試薬、サービスに分類されます。技術ベースでは、市場はPCR法、ELISA法、微生物培養法、酵素法に分類されます。用途別では、細胞株検査、ウイルス検査、生産終了細胞検査、その他に分類されます。エンドユーザー別では、学術研究機関、セルバンク、受託研究機関、製薬・バイオテクノロジー企業、その他に分類されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資ポケット
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競合の激しさ
  • 市場力学
    • 原動力
      • マイコプラズマ検査需要の急増
      • 細胞培養汚染の増加
    • 阻害要因
      • マイコプラズマ検査キットと検査機器の高コスト
    • 機会
      • 新興経済諸国は有利な機会
      • 技術的進歩の高まり
  • COVID-19市場への影響分析

第4章 マイコプラズマ検査市場：製品別

  • 概要
    • 市場規模と予測
  • 機器
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • キットと試薬
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • サービス
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第5章 マイコプラズマ検査市場：技術別

  • 概要
    • 市場規模・予測
  • PCR市場
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • ELISA法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 微生物培養技術
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 酵素法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第6章 マイコプラズマ検査市場：用途別

  • 概要
    • 市場規模と予測
  • 細胞株検査
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • ウイルス検査
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 生産終了細胞検査
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第7章 マイコプラズマ検査市場：エンドユーザー別

  • 概要
    • 市場規模と予測
  • 学術研究機関
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 細胞バンク
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 調査受託機関
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 製薬企業およびバイオテクノロジー企業
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第8章 マイコプラズマ検査市場：地域別

  • 概要
    • 市場規模・予測： 地域別
  • 北米
    • 主要動向と機会
    • 市場規模・予測：製品別
    • 市場規模・予測：技術別
    • 市場規模・予測：用途別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • 米国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • カナダ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • メキシコ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
  • 欧州
    • 主要動向と機会
    • 市場規模・予測：製品別
    • 市場規模・予測：技術別
    • 市場規模・予測：用途別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • ドイツ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • フランス
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • 英国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • イタリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • スペイン
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • その他欧州
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
  • アジア太平洋地域
    • 主要動向と機会
    • 市場規模・予測：製品別
    • 市場規模・予測：技術別
    • 市場規模・予測：用途別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • 日本
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • 中国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • オーストラリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • インド
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • 韓国市場
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • その他アジア太平洋地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
  • ラテンアメリカ・中東・アフリカ
    • 主要動向と機会
    • 市場規模・予測：製品別
    • 市場規模・予測：技術別
    • 市場規模・予測：用途別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
      • ブラジル
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • サウジアラビア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • 南アフリカ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別
      • その他の地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：製品別
      • 市場規模・予測：技術別
      • 市場規模・予測：用途別
      • 市場規模・予測：エンドユーザー別

第9章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2022年

第10章 企業プロファイル

  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories
  • Lonza
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Eurofins Scientific
  • ATCC
  • Bionique Testing Laboratories LLC
  • InvivoGen
  • Norgen Biotek Corp.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 02. MYCOPLASMA TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MYCOPLASMA TESTING MARKET FOR KITS AND REAGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. MYCOPLASMA TESTING MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 06. MYCOPLASMA TESTING MARKET FOR PCR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. MYCOPLASMA TESTING MARKET FOR ELISA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. MYCOPLASMA TESTING MARKET FOR MICROBIAL CULTURE TECHNIQUES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. MYCOPLASMA TESTING MARKET FOR ENZYMATIC METHODS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 11. MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. MYCOPLASMA TESTING MARKET FOR END OF PRODUCTION CELLS TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. MYCOPLASMA TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. MYCOPLASMA TESTING MARKET FOR CELL BANKS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. MYCOPLASMA TESTING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. MYCOPLASMA TESTING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 27. U.S. MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 28. U.S. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 29. U.S. MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. U.S. MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. CANADA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 32. CANADA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 33. CANADA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. CANADA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. EUROPE MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 50. FRANCE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. FRANCE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. UK MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. UK MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 54. UK MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. UK MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. ITALY MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 57. ITALY MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 58. ITALY MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. ITALY MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. SPAIN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 62. SPAIN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. SPAIN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. REST OF EUROPE MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 73. JAPAN MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 74. JAPAN MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 75. JAPAN MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. JAPAN MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. CHINA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 78. CHINA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 79. CHINA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. CHINA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 81. AUSTRALIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 82. AUSTRALIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 83. AUSTRALIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 84. AUSTRALIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 85. INDIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 86. INDIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 87. INDIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. INDIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH KOREA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 94. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 95. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 97. LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 98. LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 99. LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 100. LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 101. LAMEA MYCOPLASMA TESTING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 102. BRAZIL MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 103. BRAZIL MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 104. BRAZIL MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 105. BRAZIL MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 107. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 108. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 109. SAUDI ARABIA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 110. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 111. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 112. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 113. SOUTH AFRICA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 114. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 115. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
  • TABLE 116. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 117. REST OF LAMEA MYCOPLASMA TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 118. THERMO FISHER SCIENTIFIC INC. : KEY EXECUTIVES
  • TABLE 119. THERMO FISHER SCIENTIFIC INC. : COMPANY SNAPSHOT
  • TABLE 120. THERMO FISHER SCIENTIFIC INC. : PRODUCT SEGMENTS
  • TABLE 121. THERMO FISHER SCIENTIFIC INC. : SERVICE SEGMENTS
  • TABLE 122. THERMO FISHER SCIENTIFIC INC. : PRODUCT PORTFOLIO
  • TABLE 123. CHARLES RIVER LABORATORIES: KEY EXECUTIVES
  • TABLE 124. CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
  • TABLE 125. CHARLES RIVER LABORATORIES: SERVICE SEGMENTS
  • TABLE 126. CHARLES RIVER LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 127. LONZA: KEY EXECUTIVES
  • TABLE 128. LONZA: COMPANY SNAPSHOT
  • TABLE 129. LONZA: PRODUCT SEGMENTS
  • TABLE 130. LONZA: SERVICE SEGMENTS
  • TABLE 131. LONZA: PRODUCT PORTFOLIO
  • TABLE 132. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 133. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 134. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 135. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 136. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
  • TABLE 137. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
  • TABLE 138. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
  • TABLE 139. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
  • TABLE 140. EUROFINS SCIENTIFIC: KEY EXECUTIVES
  • TABLE 141. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 142. EUROFINS SCIENTIFIC: SERVICE SEGMENTS
  • TABLE 143. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 144. ATCC: KEY EXECUTIVES
  • TABLE 145. ATCC: COMPANY SNAPSHOT
  • TABLE 146. ATCC: PRODUCT SEGMENTS
  • TABLE 147. ATCC: SERVICE SEGMENTS
  • TABLE 148. ATCC: PRODUCT PORTFOLIO
  • TABLE 149. BIONIQUE TESTING LABORATORIES LLC: KEY EXECUTIVES
  • TABLE 150. BIONIQUE TESTING LABORATORIES LLC: COMPANY SNAPSHOT
  • TABLE 151. BIONIQUE TESTING LABORATORIES LLC: PRODUCT SEGMENTS
  • TABLE 152. BIONIQUE TESTING LABORATORIES LLC: SERVICE SEGMENTS
  • TABLE 153. BIONIQUE TESTING LABORATORIES LLC: PRODUCT PORTFOLIO
  • TABLE 154. INVIVOGEN: KEY EXECUTIVES
  • TABLE 155. INVIVOGEN: COMPANY SNAPSHOT
  • TABLE 156. INVIVOGEN: PRODUCT SEGMENTS
  • TABLE 157. INVIVOGEN: SERVICE SEGMENTS
  • TABLE 158. INVIVOGEN: PRODUCT PORTFOLIO
  • TABLE 159. NORGEN BIOTEK CORP.: KEY EXECUTIVES
  • TABLE 160. NORGEN BIOTEK CORP.: COMPANY SNAPSHOT
  • TABLE 161. NORGEN BIOTEK CORP.: PRODUCT SEGMENTS
  • TABLE 162. NORGEN BIOTEK CORP.: SERVICE SEGMENTS
  • TABLE 163. NORGEN BIOTEK CORP.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. MYCOPLASMA TESTING MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MYCOPLASMA TESTING MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN MYCOPLASMA TESTING MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. HIGH INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMYCOPLASMA TESTING MARKET
  • FIGURE 10. MYCOPLASMA TESTING MARKET, BY PRODUCT, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR KITS AND REAGENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR SERVICES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. MYCOPLASMA TESTING MARKET, BY TECHNOLOGY, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR PCR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR ELISA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR MICROBIAL CULTURE TECHNIQUES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR ENZYMATIC METHODS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. MYCOPLASMA TESTING MARKET, BY APPLICATION, 2022(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR CELL LINE TESTING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR VIRUS TESTING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR END OF PRODUCTION CELLS TESTING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. MYCOPLASMA TESTING MARKET, BY END USER, 2022(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR CELL BANKS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF MYCOPLASMA TESTING MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 30. MYCOPLASMA TESTING MARKET BY REGION, 2022
  • FIGURE 31. U.S. MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CANADA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. MEXICO MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. GERMANY MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. FRANCE MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. UK MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. ITALY MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SPAIN MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. REST OF EUROPE MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. JAPAN MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. CHINA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. AUSTRALIA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. INDIA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH KOREA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF ASIA-PACIFIC MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. BRAZIL MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SAUDI ARABIA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. SOUTH AFRICA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. REST OF LAMEA MYCOPLASMA TESTING MARKET, 2022-2032 ($MILLION)
  • FIGURE 50. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 54. COMPETITIVE DASHBOARD
  • FIGURE 55. COMPETITIVE HEATMAP: MYCOPLASMA TESTING MARKET
  • FIGURE 56. TOP PLAYER POSITIONING, 2022
  • FIGURE 57. THERMO FISHER SCIENTIFIC INC. : NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. THERMO FISHER SCIENTIFIC INC. : REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. CHARLES RIVER LABORATORIES: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 61. CHARLES RIVER LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. CHARLES RIVER LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. LONZA: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 64. LONZA: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 65. LONZA: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 66. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 69. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. EUROFINS SCIENTIFIC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 73. EUROFINS SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2021 (%)
目次
Product Code: A11266

The Mycoplasma Testing Market was valued at $0.7 billion in 2022 and is estimated to reach $2,243.10 million by 2032, exhibiting a CAGR of 11.7% from 2023 to 2032.

Mycoplasma Testing Market - IMG1

Mycoplasma testing is used to detect the presence of mycoplasma contamination in cell culture samples. Mycoplasma is a type of bacteria that lacks a cell wall and is difficult to detect and remove from cell cultures. Mycoplasma contamination can cause various problems in cell cultures, such as altered growth characteristics, changes in gene expression, and compromised experimental results. Therefore, it is essential to regularly test cell cultures for mycoplasma contamination to ensure the accuracy and reliability of experimental results. Mycoplasma testing is important in the process of testing vaccines, virus cultures, and other biopharmaceuticals.

The mycoplasma testing market growth is driven by an increase in demand for biologics & biosimilars, a surge in incidences of cell culture contamination, and a rise in the adoption of novel technologies for drug development. Biologics and biosimilars are complex drugs produced using living cells, and they can be contaminated by mycoplasma during the manufacturing process. Thus, regulatory bodies such as Food and Drug Administration (FDA) and European Medicines Agency (EMA) require biologics and biosimilars to be tested for mycoplasma contamination before they are approved for use. This has created a surge in demand for mycoplasma testing services. For instance, according to the IQVIA report on the Impact of Biosimilar Competition in Europe in 2021, about 9 biosimilars were approved in 2020 and 7 approved in 2021. Thus, the rise in the approval and demand for biologics & biosimilars has resulted in increased demand for mycoplasma testing.

Furthermore, the rise in incidences of cell culture contamination in the biopharmaceutical industry and the globalization of clinical trials are the key factors that boost market growth. As clinical trials are conducted across multiple countries and regions, there is a need for mycoplasma testing services that can ensure the safety of trial participants and the accuracy of trial data. This has led to an increasing demand for mycoplasma testing services and products that meet standardized testing requirements.

However, the high cost of mycoplasma testing products limits their adoption in biopharmaceutical companies, which, in turn, restrains the market growth. For instance, the cost of SouthernBiotech's Mycoplasma Detection Kit used for the detection of mycoplasma contamination in cell cultures is around $200-230. In addition, the price of culture-based mycoplasma testing service is about $250-300 per sample. Thus, the high cost of mycoplasma testing products and services negatively impacts market growth.

On the other hand, the increase in demand for mycoplasma testing in developed and developing countries such as U.S., Germany, and China is expected to create immense opportunities for the mycoplasma testing market during the forecast period.

The mycoplasma testing market is segmented on the basis of product, technology, application, end-user, and region. On the basis of product, the market is categorized into instruments, kits & reagents, and services. On the basis of technology, the market is divided into PCR, ELISA, microbial culture techniques, and enzymatic methods. On the basis of application, the market is classified into cell line testing, virus testing, end-of-production cell testing, and others. On the basis of end users, the market is segregated into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global mycoplasma testing market are: ATCC, Bionique Testing Laboratories LLC, Bio-Rad Laboratories, Inc., Charles River Laboratories, Eurofins Scientific, F. Hoffmann-La Roche Ltd., InvivoGen, Lonza, Norgen Biotek Corp., and Thermo Fisher Scientific Inc. Key players operating in the market have adopted product approval, acquisition, and product launch as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mycoplasma testing market analysis from 2022 to 2032 to identify the prevailing mycoplasma testing market opportunities.
  • Market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • An in-depth analysis of the mycoplasma testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes analysis of the regional as well as global mycoplasma testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Instruments
  • Kits and Reagents
  • Services

By Technology

  • PCR
  • ELISA
  • Microbial Culture Techniques
  • Enzymatic Methods

By Application

  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • Others

By End User

  • Academic Research Institutes
  • Cell Banks
  • Contract Research Organizations
  • Pharmaceutical and Biotechnology Companies
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • ATCC
    • Bionique Testing Laboratories LLC
    • Bio-Rad Laboratories, Inc.
    • Charles River Laboratories
    • Eurofins Scientific
    • F. Hoffmann-La Roche Ltd.
    • InvivoGen
    • Lonza
    • Norgen Biotek Corp.
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Surge in demand for mycoplasma testing
      • 3.4.1.2. Increase in incidences of cell culture contamination
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of mycoplasma testing kits and instruments
    • 3.4.3. Opportunities
      • 3.4.3.1. Developing economies offer lucrative opportunities
      • 3.4.3.2. Rise in technological advancements
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MYCOPLASMA TESTING MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Instruments
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Kits and Reagents
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Services
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: MYCOPLASMA TESTING MARKET, BY TECHNOLOGY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. PCR
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. ELISA
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Microbial Culture Techniques
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Enzymatic Methods
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: MYCOPLASMA TESTING MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Cell Line Testing
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Virus Testing
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. End of Production Cells Testing
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Others
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: MYCOPLASMA TESTING MARKET, BY END USER

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Academic Research Institutes
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Cell Banks
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Contract Research Organizations
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country
  • 7.5. Pharmaceutical and Biotechnology Companies
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by region
    • 7.5.3. Market share analysis by country
  • 7.6. Others
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by region
    • 7.6.3. Market share analysis by country

CHAPTER 8: MYCOPLASMA TESTING MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key trends and opportunities
    • 8.2.2. Market size and forecast, by Product
    • 8.2.3. Market size and forecast, by Technology
    • 8.2.4. Market size and forecast, by Application
    • 8.2.5. Market size and forecast, by End User
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Key market trends, growth factors and opportunities
      • 8.2.6.1.2. Market size and forecast, by Product
      • 8.2.6.1.3. Market size and forecast, by Technology
      • 8.2.6.1.4. Market size and forecast, by Application
      • 8.2.6.1.5. Market size and forecast, by End User
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Key market trends, growth factors and opportunities
      • 8.2.6.2.2. Market size and forecast, by Product
      • 8.2.6.2.3. Market size and forecast, by Technology
      • 8.2.6.2.4. Market size and forecast, by Application
      • 8.2.6.2.5. Market size and forecast, by End User
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Key market trends, growth factors and opportunities
      • 8.2.6.3.2. Market size and forecast, by Product
      • 8.2.6.3.3. Market size and forecast, by Technology
      • 8.2.6.3.4. Market size and forecast, by Application
      • 8.2.6.3.5. Market size and forecast, by End User
  • 8.3. Europe
    • 8.3.1. Key trends and opportunities
    • 8.3.2. Market size and forecast, by Product
    • 8.3.3. Market size and forecast, by Technology
    • 8.3.4. Market size and forecast, by Application
    • 8.3.5. Market size and forecast, by End User
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Key market trends, growth factors and opportunities
      • 8.3.6.1.2. Market size and forecast, by Product
      • 8.3.6.1.3. Market size and forecast, by Technology
      • 8.3.6.1.4. Market size and forecast, by Application
      • 8.3.6.1.5. Market size and forecast, by End User
      • 8.3.6.2. France
      • 8.3.6.2.1. Key market trends, growth factors and opportunities
      • 8.3.6.2.2. Market size and forecast, by Product
      • 8.3.6.2.3. Market size and forecast, by Technology
      • 8.3.6.2.4. Market size and forecast, by Application
      • 8.3.6.2.5. Market size and forecast, by End User
      • 8.3.6.3. UK
      • 8.3.6.3.1. Key market trends, growth factors and opportunities
      • 8.3.6.3.2. Market size and forecast, by Product
      • 8.3.6.3.3. Market size and forecast, by Technology
      • 8.3.6.3.4. Market size and forecast, by Application
      • 8.3.6.3.5. Market size and forecast, by End User
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Key market trends, growth factors and opportunities
      • 8.3.6.4.2. Market size and forecast, by Product
      • 8.3.6.4.3. Market size and forecast, by Technology
      • 8.3.6.4.4. Market size and forecast, by Application
      • 8.3.6.4.5. Market size and forecast, by End User
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Key market trends, growth factors and opportunities
      • 8.3.6.5.2. Market size and forecast, by Product
      • 8.3.6.5.3. Market size and forecast, by Technology
      • 8.3.6.5.4. Market size and forecast, by Application
      • 8.3.6.5.5. Market size and forecast, by End User
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Key market trends, growth factors and opportunities
      • 8.3.6.6.2. Market size and forecast, by Product
      • 8.3.6.6.3. Market size and forecast, by Technology
      • 8.3.6.6.4. Market size and forecast, by Application
      • 8.3.6.6.5. Market size and forecast, by End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key trends and opportunities
    • 8.4.2. Market size and forecast, by Product
    • 8.4.3. Market size and forecast, by Technology
    • 8.4.4. Market size and forecast, by Application
    • 8.4.5. Market size and forecast, by End User
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Key market trends, growth factors and opportunities
      • 8.4.6.1.2. Market size and forecast, by Product
      • 8.4.6.1.3. Market size and forecast, by Technology
      • 8.4.6.1.4. Market size and forecast, by Application
      • 8.4.6.1.5. Market size and forecast, by End User
      • 8.4.6.2. China
      • 8.4.6.2.1. Key market trends, growth factors and opportunities
      • 8.4.6.2.2. Market size and forecast, by Product
      • 8.4.6.2.3. Market size and forecast, by Technology
      • 8.4.6.2.4. Market size and forecast, by Application
      • 8.4.6.2.5. Market size and forecast, by End User
      • 8.4.6.3. Australia
      • 8.4.6.3.1. Key market trends, growth factors and opportunities
      • 8.4.6.3.2. Market size and forecast, by Product
      • 8.4.6.3.3. Market size and forecast, by Technology
      • 8.4.6.3.4. Market size and forecast, by Application
      • 8.4.6.3.5. Market size and forecast, by End User
      • 8.4.6.4. India
      • 8.4.6.4.1. Key market trends, growth factors and opportunities
      • 8.4.6.4.2. Market size and forecast, by Product
      • 8.4.6.4.3. Market size and forecast, by Technology
      • 8.4.6.4.4. Market size and forecast, by Application
      • 8.4.6.4.5. Market size and forecast, by End User
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Key market trends, growth factors and opportunities
      • 8.4.6.5.2. Market size and forecast, by Product
      • 8.4.6.5.3. Market size and forecast, by Technology
      • 8.4.6.5.4. Market size and forecast, by Application
      • 8.4.6.5.5. Market size and forecast, by End User
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Key market trends, growth factors and opportunities
      • 8.4.6.6.2. Market size and forecast, by Product
      • 8.4.6.6.3. Market size and forecast, by Technology
      • 8.4.6.6.4. Market size and forecast, by Application
      • 8.4.6.6.5. Market size and forecast, by End User
  • 8.5. LAMEA
    • 8.5.1. Key trends and opportunities
    • 8.5.2. Market size and forecast, by Product
    • 8.5.3. Market size and forecast, by Technology
    • 8.5.4. Market size and forecast, by Application
    • 8.5.5. Market size and forecast, by End User
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Key market trends, growth factors and opportunities
      • 8.5.6.1.2. Market size and forecast, by Product
      • 8.5.6.1.3. Market size and forecast, by Technology
      • 8.5.6.1.4. Market size and forecast, by Application
      • 8.5.6.1.5. Market size and forecast, by End User
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Key market trends, growth factors and opportunities
      • 8.5.6.2.2. Market size and forecast, by Product
      • 8.5.6.2.3. Market size and forecast, by Technology
      • 8.5.6.2.4. Market size and forecast, by Application
      • 8.5.6.2.5. Market size and forecast, by End User
      • 8.5.6.3. South Africa
      • 8.5.6.3.1. Key market trends, growth factors and opportunities
      • 8.5.6.3.2. Market size and forecast, by Product
      • 8.5.6.3.3. Market size and forecast, by Technology
      • 8.5.6.3.4. Market size and forecast, by Application
      • 8.5.6.3.5. Market size and forecast, by End User
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Key market trends, growth factors and opportunities
      • 8.5.6.4.2. Market size and forecast, by Product
      • 8.5.6.4.3. Market size and forecast, by Technology
      • 8.5.6.4.4. Market size and forecast, by Application
      • 8.5.6.4.5. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

  • 10.1. Thermo Fisher Scientific Inc.
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
  • 10.2. Charles River Laboratories
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
  • 10.3. Lonza
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
  • 10.4. F. Hoffmann-La Roche Ltd.
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
    • 10.4.6. Business performance
  • 10.5. Bio-Rad Laboratories, Inc.
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
  • 10.6. Eurofins Scientific
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
    • 10.6.6. Business performance
  • 10.7. ATCC
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
  • 10.8. Bionique Testing Laboratories LLC
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
  • 10.9. InvivoGen
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
  • 10.10. Norgen Biotek Corp.
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio